


This article was downloaded by: [Flinders University of South Australia]

On: 02 January 2015, At: 19:08

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office:

Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

New Total Synthesis of O-Methyledegeworin and Edgeworin

B. Serge Kirkiacharian^a & Marie Brillard^a

^a Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie, Chatenay Malabry Cedex, France

Published online: 16 Aug 2006.

To cite this article: B. Serge Kirkiacharian & Marie Brillard (2006) New Total Synthesis of O-Methyledegeworin and Edgeworin, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 36:5, 541-546

To link to this article: <http://dx.doi.org/10.1080/00397910500406088>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

New Total Synthesis of O-Methyledegeworin and Edgeworin

B. Serge Kirkiacharian and Marie Brillard

Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie Chatenay
Malabry Cedex, France

Abstract: Upon thermal condensation of diethyl (coumarinyl-7-oxy)malonate with O-methyl-resorcine, the corresponding bis[coumarinyl]ether, 4-hydroxy-O-methyledegeworin is obtained in good yield. This leads to 4-bromo-O-methyledegeworin, O-methyledegeworin, and edgeworin.

Keywords: Bis[coumarinyl]ethers, edgeworin, O-methyledegeworin

INTRODUCTION

The 3,7'-bis[coumarinyl]ethers constitute a group of naturally occurring oxygen heterocyclic compounds, isolated principally in the *Thymeliaceae* but also in the *Leguminosae* and *Rutaceae* families: edgeworin **1** and daphnoretin **2** from *Edgeworthia chrysantha*,^[1] daphnoretin **2** and O-methyl-daphnoretin **3** from *Daphne mezereum*, various other plants,^[2,3] and more recently from *Artemisia keiskeana*,^[4] and edgeworthin **4** from *Edgeworthia gardneri*^[5] (Figure 1). Besides their phytochemical interest, the 3,7'-bis[coumarinyl]ethers present interesting biological properties. Daphnoretin inhibits the growth of Ehrlich ascites carcinoma in mice,^[6] DNA-producing enzymes,^[7] and nucleic acid synthesis,^[8] whereas edgeworin, edgeworthin, and daphnoretin inhibit the lyase activity of DNA polymerase β , providing useful agents for adjuvant cancer therapy.^[9]

Received in Poland July 15, 2005

Address correspondence to B. Serge Kirkiacharian, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie de Paris-Sud, 5, rue J.B. Clément, 92296 Chatenay Malabry Cedex, France. E-mail: serge.kirkiacharian@cep.u-psud.fr




Figure 1. Reference structures.

However, the discovery of phenprocoumon **6** and warfarin **7** as lead templates to the human immunodeficiency virus protease (HIV-PR) led to the identification of various 3-substituted 4-hydroxy-coumarins as active nonpeptide HIV-PR inhibitors,^[10,11] opening up a new therapeutic possibility (Figure 1).

During the course of a research program in connexion with the preparation of potential HIV-1 PR inhibitors, we investigated the structure–activity relationships of various 3-substituted-4-hydroxycoumarins.^[12] Therefore, we synthesized 4-hydroxy-O-methylegeworin, which led us also to the synthesis of the natural compounds O-methylegeworin and edgeworin.

There are some available routes for the synthesis 3,7'-bis[coumarinyl]ethers:

O-Methyldaphnoretin **4** was prepared by the Williamson condensation of 3-bromo-6,7-dimethoxycoumarin and 7-hydroxycoumarin using copper powder with a low yield.^[2]

O-Methyldaphnoretin **4** and some 3,7'-bis[coumarinyl]ethers were prepared by Perkin reactions of N,N-diethylcoumarin-7-oxyacetamide^[13] or (coumarinyl-7-oxy)acetic acid^[14] with conveniently substituted salicylaldehydes.

Daphnoretin **2** derivatives were obtained via the corresponding 4-hydroxy-3,7'-bis[coumarinyl]ethers prepared by thermal condensation of diethyl (coumarinyl-7-oxy)malonate with conveniently substituted phenols.^[15]

Among the previously reported procedures leading to 3,7'-bis[coumarinyl]ethers, the last one is more satisfactory for the following reasons:

It leads to derivatives substituted by a 4-hydroxy group, which is necessary as much for their bonding to the HIV-PR as for their inhibitory potency.^[16]

Besides their antithrombotic activity, the 3-substituted 4-hydroxycoumarins present interesting free-radical scavenging properties.^[17]

The synthesis of O-methyledgeworin and edgeworin could be performed starting from the corresponding 4-hydroxy-7-methoxy-3,7'-bis[coumarinyl] ether **10a**.


RESULTS

The thermal condensation was therefore selected and performed by reaction of O-methyl-resorcine **8** and diethyl (coumarinyl-7-oxy)malonate **9**. The expected 4-hydroxy-O-methyledgeworin **10a** was obtained with good yield. The synthesis of O-methyledgeworin **2** was achieved in two steps by removing the 4-hydroxy group after formation of 4-bromo-O-methyledgeworin **10b** using phosphorus oxybromide followed by the reductive debromination. Edgeworin **1** was finally obtained from compound **2** by demethylation with aluminium chloride (Scheme 1).

The structure of the compounds **10a**, **10b**, **2**, and **1** was established by elemental analysis, IR, and ^1H NMR spectroscopy. The chemical shifts of the NMR spectra are in agreement with those already reported for various 3-substituted 4-hydroxycoumarins^[18] and for O-methyledgeworin and edgeworin.^[1,14]

EXPERIMENTAL

The purity of all the compounds was routinely checked on 'Merck' 60 F₂₅₄ silica-gel plates, and the spots were located by UV lamp. Melting points (mp) were taken on a Kofler bench and are uncorrected. IR spectra were recorded on a Perkin-Elmer 177 spectrophotometer and ^1H spectra on a Bruker AC 200 spectrometer. Glass equipment was dried at 100°C in an oven prior to use when anhydrous conditions were required.



Scheme 1. Total synthesis of O-methyledgeworin and edgeworin.

Synthesis of Compounds 10a, 10b, 2, and 1

3-(7-Coumarinyloxy)-4-hydroxy-7-methoxycoumarin 10a (4-hydroxy-O-methyl-edge-worin, C₁₉H₁₂O₇). In a dry, round-bottom flask equipped with an argon bubbler and a Vigreux distillation column, a mixture of O-methyl-resorcinol (2.48 g, 2.0 mmol), diethyl coumarinyl-7-oxy)malonate^[19] (7.44 g, 2.2 mmol), and diphenylether (5.0 mL) is heated at 250°C for 5 h (the progress of the reaction is monitored by TLC). The reaction mixture is evaporated under reduced pressure on a rotary evaporator. The cooled mixture is then triturated with diethylether (5 mL), giving a white solid, which is filtered and washed with a small portion of diethylether (5.0 mL). The solid is crystallized in acetic acid and in an ethanol–THF–water mixture (7/2/1), Yield 4.55 g (65%); mp 325°C.

IR (cm⁻¹): 3078, 1688, 1610, 1236, 1129, 1076, 834. ¹H NMR (DMSO-d₆): 3.88 (s, 3H, OCH₃), 6.33 (d, *J* = 9.4 Hz, 1H), 7.0–7.06 (m, 4H), 7.66 (d, *J* = 9.4 Hz, 1H), 7.82 (d, *J* = 9.6 Hz, 1H), 8.02 (d, *J* = 9.6 Hz, 1H). Anal. calcd. for C₁₉H₁₂O₇: C, 64.78; H, 3.43. Found: C, 64.43; H, 3.36.

Acetate (C₂₁H₁₄O₈): mp: 283°C. IR (cm⁻¹): 3422, 1719, 1612, 1274, 1256, 1123, 849. ¹H NMR (DMSO-d₆): 2.36 (s, 3H, CH₃), 3.91 (s, 3H, OCH₃), 6.30 (d, *J* = 9.4 Hz, 1H), 6.93–7.00 (m, 4H), 7.39–7.48 (m, 2H), 7.64 (d, *J* = 9.8 Hz, 1H).

Tosylate (C₂₆H₁₈O₉S): mp: 238°C. IR (cm⁻¹): 3087, 1722, 1614, 1392, 1371, 1254, 1132, 1058, 731. ¹H NMR (DMSO-d₆): 2.39 (s, 3H, CH₃), 3.91 (s, 3H, OCH₃), 6.30 (d, *J* = 9.4 Hz, 1H), 6.85 (dd, *J* = 8.6 Hz and 2.6 Hz, 1H), 6.96 (d, *J* = 2.2 Hz, 1H), 7.07 (d, *J* = 2.2 Hz, 1H), 7.10 (dd, *J* = 8.8 Hz and 2.2 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.59 (d, 8.6 Hz, 1H), 7.85 (d, 8.4 Hz, 1H), 8.00 (d, *J* = 9.6 Hz, 1H).

3-(7-Coumarinyloxy)-4-bromo-7-methoxycoumarin 10b (4-bromo-O-methyl-edgeworin, C₁₉H₁₁BrO₆). In a dry, 100 mL, double-necked, round-bottom flask fitted with a magnetic stirring bar and a reflux condenser protected with a CaCl₂ drying tube, 1.0 g (2.8 mmol) of 4-hydroxy-O-methyl-edgeworin **10**, 0.9 g (31 mmol) of phosphorus oxybromide, and 1,2-dichlorobenzene (40 mL) are introduced. The mixture is heated under reflux for 8 h (the progress of the reaction is monitored by TLC). The solvent is concentrated to 10 mL under reduced pressure, and the crude mixture is purified by column chromatography over silica gel (solvent: CHCl₃) to give 0.767 g (yield: 66%) of pure product. Mp: 230°C. IR (cm⁻¹): 3074, 2918, 2850, 1714, 1611, 1249, 1120, 835. ¹H NMR (DMSO-d₆): 3.91 (s, 3H, OCH₃), 6.37 (d, *J* = 9.6 Hz, 1H), 7.08–7.21 (m, 3H), 7.29 (d, *J* = 2.4 Hz, 1H), 7.71 (d, *J* = 8.6 Hz, 1H), 7.76 (d, *J* = 8.6 Hz, 1H), 8.02 (dd, *J* = 9.4 Hz, 1H). Anal. calcd. for C₁₉H₁₁BrO₆: C, 54.96; H, 2.67. Found: C, 54.43; H, 2.46.

3-(7-Coumarinyloxy)-7-methoxycoumarin 2 (O-methyl-edgeworin C₁₉H₁₂O₆). In a 200 mL, double-necked, round-bottom flask fitted with a magnetic stirring

bar and a reflux condenser, 3-(7-coumarinyloxy)-4-bromo-7-methoxycoumarin **10b** (0.400 g, 0.964 mmol), zinc powder (1.4 g), ethanol (100 mL), and concentrated hydrochloric acid (2.0 mL) are introduced. The mixture refluxed for 1.0 h. Another portion of zinc powder (1.4 g) and hydrochloric acid (2.0 mL) are added, and the mixture refluxed again for 30 min (the TLC showed the end of the reaction). The mixture was filtered, ethanol distilled, and crushed ice added to the residue. The separated solid was filtered, washed with water, and dried to yield 0.252 g (78%), Mp: 220°C, lit. 215°C.^[14] IR (cm⁻¹): 3085, 2920, 2850, 1714, 1611, 1249, 1120. ¹H NMR (DMSO-d₆): 3.91 (s, 3H, OCH₃); 6.37 (d, *J* = 9.6 Hz, 1H); 7.08–7.21 (m, 3H); 7.29 (d, *J* = 2.4 Hz, 1H); 7.71 (d, *J* = 8.6 Hz, 1H); 7.76 (d, *J* = 8.6 Hz, 1H); 8.02 (dd, *J* = 9.4 Hz, 1H).

3-(7-Coumarinyloxy)-7-hydroxycoumarin 1 (edgeworin, C₁₈H₁₀O₆). O-Methylegeworin (0.10 g) and aluminium chloride (1.0 g) in dichloromethane (40 mL) are stirred at room temperature for 48 h. The solvent is evaporated, 50 mL of 10% hydrochloric acid is added, and the mixture is stirred for 1 h. A brown solid is recovered by filtration. The recovered solid is purified by column chromatography over silica gel (solvent ethyl acetate–toluene, 5/7), giving 0.080 g of edgeworin (yield: 84%). Mp 283°C, lit. 284–296°C,^[11] 283°C.^[14] IR (cm⁻¹): 3352, 2917, 1707, 1610, 1391, 1262, 1235, 1132, 1081, 847. ¹H NMR (DMSO-d₆): 6.37 (d, *J* = 9.6 Hz); 6.81 (dd, *J* = 5 Hz and 2.2 Hz, 1H); 6.87 (d, *J* = 2.2 Hz, 1H); 7.11 (dd, *J* = 8.6 Hz and 2.4 Hz); 7.18 (d, *J* = 2.2 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 1H); 7.70 (d, 8.6 Hz, 1H); 7.92 (s, 1H), 8.03 (d, *J* = 9.6 Hz, 1H); 12.9 (s b, 1H).

REFERENCES

1. Baba, K.; Tabata, Y.; Taniguti, M.; Rozawa, M. Coumarins from *Edgeworthia chrysantha*. *Phytochemistry* **1989**, *28*, 221.
2. Tschesche, R.; Schacht, U.; Legler, G. Daohnoretin, a naturally occurring derivative of 3,7'-dicoumaryl ether. *Liebigs Ann. Chem.* **1963**, *662*, 113.
3. Cordell, G. A. Studies in the thymeliaceae I. NMR spectral assignments of daphnoretin. *J. Nat. Prod.* **1984**, *47*, 84.
4. Kwak, J. H.; Lee, K. B.; Schmitz, F. J. Four new coumlarin derivatives from *Artemisia keskeana*. *J. Nat. Prod.* **2001**, *64*, 1081.
5. Mujumbar, P. L.; Sengupta, G. C.; Dinda, B. N.; Chatterjea, A. Edgeworthin, a new bis-coumarin from *Edgeworthia gardneri*. *Phytochemistry* **1974**, *13*, 1929.
6. Torrance, S. J.; Hoffmann, J. J.; Cole, J. R. Wikstroemol, antitumor lignan from *Wikstroemia foetida* var. oahuensis Gray and *Wikstroemia uva-ursi* Gray (thymelaeaceae). *J. Pharm. Sci.* **1979**, *68*, 664.
7. Liou, Y. F.; Hall, I. H.; Lee, K. H. Antitumor agents LIV: The effects of daphnoretin on in vitro protein synthesis of Erlich ascites carcinoma cells and other tissues. *J. Pharm. Sci.* **1982**, *71*, 745.
8. Hall, I. H.; Tagahara, K.; Lee, K. H. Antitumor agents LIII: The effects of daphnoretin on nucleic acid protein synthesis of Erlich ascites tumor cells. *J. Pharm. Sci.* **1982**, *71*, 741.

9. Li, S.-S.; Feng, X. G.; Hecht, S. M. Biscoumarin derivatives from *Edgeworthia gardneri* that inhibit the lyase activity of DNA polymerase β . *J. Nat. Prod.* **2004**, *67*, 1608–1610.
10. Thairgivongs, S. T.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C. P. Structure-based design of HIV protease inhibitors: 4-Hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptide inhibitors. *J. Med. Chem.* **1994**, *37*, 3200.
11. Tummino, P. J.; Ferguson, D.; Hupe, D. Competitive inhibition of HIV-1 protease by warfarin derivatives. *Biochem. Biophys. Res. Commun.* **1994**, *201*, 290.
12. Kirkiacharian, B. S.; Duong Than, T.; Sames, S.; Bakhchinian, R.; Kurkjian, R.; Tonnaire, T. Structure–activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors. *Il Farmaco* **2002**, *57*, 703.
13. Phadke, C. P.; Kelkar, S. L.; Wadia, M. S. Synthesis of dicoumaryl ethers. Synthesis of daphnoretin methyl ether. *Synthesis* **1986**, 413–414.
14. Deshpande, A. R.; Thombre, H. M.; Natu, A. D.; Paradkar, M. V. A convenient synthesis of 3,7'-bis(coumarinyl)ethers: Synthesis of edgeworin. *Indian J. Chem.* **1992**, *31B*, 759.
15. Kirkiacharian, B. S.; Mentzer, C. Sur une nouvelle synthèse de l'éther méthylique de la daphnorétine. *C. R. Acad. Sci.* **1965**, *260*, 197; Confirmation par synthèse totale de la structure de la daphnorétine. *Bull. Soc. Chim. Fr.* **1966**, 770.
16. Wlodawer, A.; Erickson, J. W. Structure-based inhibitors of HIV-1 protease. *Ann. Rev. Biochem.* **1993**, *62*, 543.
17. Kirkiacharian, B. S.; Bakhchinian, R.; Chidiack, H.; Mazmanian, M.; Planché, C. Activité antiradicalaire de dérivés substitués de la 4-hydroxycoumarine. *Ann. Pharm. Fr.* **1999**, *57*, 251.
18. (a) Kirkiacharian, B. S.; Rabaron, A.; Plat, M. Etude par RMN du ^{13}C de quelques hydroxy-4 coumarines anticoagulantes. *C. R. Acad. Sci.* **1977**, *284*, 697; (b) Rabaron, A.; Didry, J. R.; Kirkiacharian, B. S.; Plat, M. Etude par RMN du ^{13}C d'Hydroxy-4 coumarines substituées en 3. Analyse par Corrélation des Effets de Substituants. *Org. Magn. Res.* **1979**, *12*, 284.
19. Kirkiacharian, B. S.; Mentzer, C. Nouveaux esters aryloxy-maloniques et hétérocycliques et produits obtenus. French Patent P.V. 98794, 1964.